Conduit Pharmaceuticals, known in the stock market as CDT.US, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC). On September 10, 2024, at 5:00 P.M., the SEC granted effectiveness to the company's Form F-1 filing. This development is a critical step for Conduit Pharmaceuticals, which operates under the legal name Genius Group Ltd, as indicated by its CIK number 0001847806. The effectiveness of the Form F-1, associated with file number 333-279795, marks a pivotal moment for the company's future financial activities.

Conduit Pharmaceuticals, known in the stock market as CDT.US, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC). On September 10, 2024, at 5:00 P.M., the SEC granted effectiveness to the company's Form F-1 filing. This development is a critical step for Conduit Pharmaceuticals, which operates under the legal name Genius Group Ltd, as indicated by its CIK number 0001847806. The effectiveness of the Form F-1, associated with file number 333-279795, marks a pivotal moment for the company's future financial activities.